(Q37773255)

22 August 2017

1 reference

title

HER-2/neu as a target for cancer vaccines (English)

1 reference

22 August 2017

Constantin N Baxevanis

1

1 reference

22 August 2017

Ioannis F Voutsas

2

1 reference

22 August 2017

Angelos D Gritzapis

3

1 reference

22 August 2017

Sonia A Perez

4

1 reference

22 August 2017

Michael Papamichail

5

1 reference

22 August 2017

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

2

1 reference

22 August 2017

2

1 reference

22 August 2017

213-226

1 reference

Progress in human tumour immunology and immunotherapy

22 August 2017

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

21 January 2018

1 reference

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the ?-chain from Fc(?) RI

21 January 2018

1 reference

Cellular immunity to the Her-2/neu protooncogene

21 January 2018

1 reference

Immunogenic HER-2/neu peptides as tumor vaccines

21 January 2018

1 reference

21 January 2018

Cancer immunotherapy.

1 reference

Use of tumour-responsive T cells as cancer treatment

21 January 2018

1 reference

The E75 HER2/neu peptide vaccine

21 January 2018

1 reference

Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self.

21 January 2018

1 reference

Projection of an immunological self shadow within the thymus by the aire protein

21 January 2018

1 reference

An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains

21 January 2018

1 reference

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

21 January 2018

1 reference

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity

21 January 2018

1 reference

Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance

21 January 2018

1 reference

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice

21 January 2018

1 reference

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties

21 January 2018

1 reference

Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain.

21 January 2018

1 reference

Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.

21 January 2018

1 reference

Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma

21 January 2018

1 reference

Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent

21 January 2018

1 reference

Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules

21 January 2018

1 reference

Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.

21 January 2018

1 reference

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes

21 January 2018

1 reference

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

21 January 2018

1 reference

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

21 January 2018

1 reference

Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors

21 January 2018

1 reference

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

Calcium influx and the Ca2+-calmodulin complex are involved in interferon-gamma-induced expression of HLA class II molecules on HL-60 cells

21 January 2018

1 reference

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones

21 January 2018

1 reference

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope

21 January 2018

1 reference

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

Mini-review CD4 T cells are required for CD8 T cell memory generation

21 January 2018

1 reference

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

21 January 2018

1 reference

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

21 January 2018

1 reference

The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells

21 January 2018

1 reference

Vaccines for tumour prevention

21 January 2018

1 reference

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

21 January 2018

1 reference

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

21 January 2018

1 reference

Development of vaccines for high-risk ductal carcinoma in situ of the breast

21 January 2018

1 reference

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

21 January 2018

1 reference

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

21 January 2018

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients

21 January 2018

1 reference

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients

21 January 2018

1 reference

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

21 January 2018

1 reference

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

21 January 2018

1 reference

Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern

21 January 2018

1 reference

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.

21 January 2018

1 reference

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

21 January 2018

1 reference

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain

21 January 2018

1 reference

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

Denileukin diftitox: a novel immunotoxin

21 January 2018

1 reference

Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

21 January 2018

1 reference

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

Targeting the stroma by T cells to limit tumor growth

21 January 2018

1 reference

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

21 January 2018

1 reference

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells

21 January 2018

1 reference

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

21 January 2018

1 reference

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

21 January 2018

1 reference

Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.

21 January 2018

1 reference

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

21 January 2018

1 reference

Vaccination for treatment and prevention of cancer in animal models.

21 January 2018

1 reference

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

21 January 2018

1 reference

Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer

21 January 2018

1 reference

CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity

21 January 2018

1 reference

Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.09.89

1 reference

22 August 2017

1 reference